Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/106923
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Naranjo Hernández, Antonio | en_US |
dc.contributor.author | Molina, Amparo | en_US |
dc.contributor.author | Quevedo, Adrián | en_US |
dc.contributor.author | Rubiño, Francisco J. | en_US |
dc.contributor.author | Sánchez-Alonso, Fernando | en_US |
dc.contributor.author | Rodríguez-Lozano, Carlos | en_US |
dc.contributor.author | Ojeda, Soledad | en_US |
dc.date.accessioned | 2021-04-19T15:22:41Z | - |
dc.date.available | 2021-04-19T15:22:41Z | - |
dc.date.issued | 2021 | en_US |
dc.identifier.issn | 1862-3522 | en_US |
dc.identifier.other | Scopus | - |
dc.identifier.uri | http://hdl.handle.net/10553/106923 | - |
dc.description.abstract | Summary: We analyzed the long-term persistence of treatment in a FLS. During follow-up, 15.2% of patients had a refracture and 23.8% died. At the 5-year checkup, 74% had started treatment (associated with female sex, previous use of bisphosphonate, and referral to an osteoporosis clinic). Persistence at 1 and 5 years was 70.6% and 46.5%, respectively. Introduction: To analyze the long-term persistence of treatment in a fracture liaison service (FLS). Methods: Patients ≥ 50 years with a fragility fracture attended between 2012 and 2016 who were recommended for treatment to prevent new fractures were included. Baseline data included demographics, type of fracture, previous treatment, and FRAX® items. Five years later, patient records were reviewed and the following data were collected: [1] survival; [2] refracture; [3] initiation of treatment, persistence, and medication possession ratio (MPR) > 80%. Results: We included 888 patients, mean age 75 years, 83% women, and mean follow-up 56 months. During follow-up, 135 patients (15.2%) had a refracture (109 major fractures, 50 hip refractures) and 212 patients died (23.8%); at the 5-year checkup, 657 patients (74%) had started some type of treatment. Factors associated with the start of treatment were female sex (OR 2.10; 95% CI: 1.42–3.11), previous use of bisphosphonate (OR 3.91; 95% CI: 2.23–6.86), and referral to an osteoporosis clinic (OR 1.46; 95% CI: 1.02–2.07). Persistence decreased from 70.6% at 12 months to 46.5% at 60 months. An MPR > 80% was confirmed in 449 patients, 68.3% of whom were under treatment. A total of 521 and 447 patients received treatment for at least 24 and 36 months, respectively (79.3% and 68.0% of those who started treatment). Conclusions: Patients with fragility fractures attended at an FLS showed optimal long-term persistence of treatment. These data can help healthcare managers better calculate the cost-effectiveness of implementing the FLS model. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Archives of Osteoporosis | en_US |
dc.source | Archives of Osteoporosis [ISSN 1862-3522], v. 16 (1), 60, (Diciembre 2021) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320714 Osteopatología | en_US |
dc.subject.other | Adherence | en_US |
dc.subject.other | Bisphosphonate | en_US |
dc.subject.other | Fracture | en_US |
dc.subject.other | Fracture Liaison Service | en_US |
dc.subject.other | Osteoporosis | en_US |
dc.subject.other | Persistence | en_US |
dc.title | Fracture liaison service model: treatment persistence 5 years later | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1007/s11657-021-00925-6 | en_US |
dc.identifier.scopus | 85103814987 | - |
dc.contributor.authorscopusid | 7003297397 | - |
dc.contributor.authorscopusid | 57198189392 | - |
dc.contributor.authorscopusid | 57222724280 | - |
dc.contributor.authorscopusid | 57211988115 | - |
dc.contributor.authorscopusid | 56589016600 | - |
dc.contributor.authorscopusid | 6603136298 | - |
dc.contributor.authorscopusid | 57198031414 | - |
dc.identifier.eissn | 1862-3514 | - |
dc.identifier.issue | 1 | - |
dc.relation.volume | 16 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Diciembre 2021 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,693 | |
dc.description.jcr | 2,879 | |
dc.description.sjrq | Q2 | |
dc.description.jcrq | Q2 | |
dc.description.scie | SCIE | |
dc.description.miaricds | 10,7 | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | GIR IUIBS: Grupo de investigaciones infecciosas, nutricionales e inflamatorias en pacientes hospitalarios / Study Group on infectious, nutritional and inflammatory diseases in hospitalized patients | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-2013-6664 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Naranjo Hernández, Antonio | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
13
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
10
checked on Mar 30, 2025
Page view(s)
135
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.